BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Polyzos SA, Bugianesi E, Kountouras J, Mantzoros CS. Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists. Metabolism 2017;66:64-8. [PMID: 27594084 DOI: 10.1016/j.metabol.2016.08.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Tung YT, Zeng JL, Ho ST, Xu JW, Li S, Wu JH. Anti-NAFLD Effect of Djulis Hull and Its Major Compound, Rutin, in Mice with High-Fat Diet (HFD)-Induced Obesity. Antioxidants (Basel) 2021;10:1694. [PMID: 34829565 DOI: 10.3390/antiox10111694] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021;54:1013-25. [PMID: 34416040 DOI: 10.1111/apt.16575] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
3 Sohouli MH, Sayyari AA, Lari A, Nameni G, Lotfi M, Fatahi S, Saneie S, Găman MA, Moodi F, Raee P, Aghamiri S, Rayi A, Shahriari A, Moodi V. Association of dietary insulinaemic potential and odds of non-alcoholic fatty liver disease among adults: A case-control study. J Hum Nutr Diet 2021;34:901-9. [PMID: 33586811 DOI: 10.1111/jhn.12865] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Polyzos SA, Kountouras J. Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis. Annals of Hepatology 2020;19:579-80. [DOI: 10.1016/j.aohep.2020.07.001] [Reference Citation Analysis]
5 Polyzos SA, Mantzoros CS. Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metabolism 2020;111S:154318. [PMID: 32707055 DOI: 10.1016/j.metabol.2020.154318] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
6 Doumas M, Imprialos K, Stavropoulos K, Athyros VG. Pharmacological Management of Type 2 Diabetes Complications. Curr Vasc Pharmacol 2020;18:101-3. [PMID: 32013814 DOI: 10.2174/157016111802200101155519] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Boutari C, Bouzoni E, Joshi A, Stefanakis K, Farr OM, Mantzoros CS. Metabolism updates: new directions, techniques, and exciting research that is broadening the horizons. Metabolism 2020;102:154009. [PMID: 31715175 DOI: 10.1016/j.metabol.2019.154009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Katsiki N, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease and colorectal cancer: A marker of risk or common causation? Metabolism 2018;87:A10-3. [DOI: 10.1016/j.metabol.2018.08.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
9 Kong M, Chen X, Xu H, Wenping, Fang M, Xu Y. Hepatocyte-specific deletion of Brg1 alleviates methionine-and-choline-deficient diet (MCD) induced non-alcoholic steatohepatitis in mice. Biochem Biophys Res Commun 2018;503:344-51. [PMID: 29890136 DOI: 10.1016/j.bbrc.2018.06.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
10 Shu Z, He W, Shahen M, Guo Z, Shu J, Wu T, Bian X, Shar AH, Farag MR, Alagawany M, Liu C. Clarifying of the potential mechanism of Sinisan formula for treatment of chronic hepatitis by systems pharmacology method. Biomed Pharmacother 2018;100:532-50. [PMID: 29482047 DOI: 10.1016/j.biopha.2018.02.047] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
11 Boutari C, Perakakis N, Mantzoros CS. Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul). 2018;33:33-43. [PMID: 29589386 DOI: 10.3803/enm.2018.33.1.33] [Cited by in Crossref: 61] [Cited by in F6Publishing: 80] [Article Influence: 15.3] [Reference Citation Analysis]
12 Zhang X, Yang W, Wang J, Meng Y, Guan Y, Yang J. FAM3 gene family: A promising therapeutical target for NAFLD and type 2 diabetes. Metabolism 2018;81:71-82. [PMID: 29221790 DOI: 10.1016/j.metabol.2017.12.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
13 Wang W, Xu MJ, Cai Y, Zhou Z, Cao H, Mukhopadhyay P, Pacher P, Zheng S, Gonzalez FJ, Gao B. Inflammation is independent of steatosis in a murine model of steatohepatitis. Hepatology 2017;66:108-23. [PMID: 28220523 DOI: 10.1002/hep.29129] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]